- Home
- CYRX vs TRML Comparison
CYRX vs TRML Comparison
Compare CYRX & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- TRML
- Stock Information
- Founded
- CYRX 1999
- TRML 2021
- Country
- CYRX United States
- TRML United States
- Employees
- CYRX N/A
- TRML N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- TRML Health Care
- Exchange
- CYRX Nasdaq
- TRML Nasdaq
- Market Cap
- CYRX 405.4M
- TRML 419.1M
- IPO Year
- CYRX N/A
- TRML N/A
- Fundamental
- Price
- CYRX $6.56
- TRML $23.01
- Analyst Decision
- CYRX Buy
- TRML Strong Buy
- Analyst Count
- CYRX 7
- TRML 3
- Target Price
- CYRX $13.14
- TRML $65.00
- AVG Volume (30 Days)
- CYRX 457.9K
- TRML 187.7K
- Earning Date
- CYRX 11-07-2024
- TRML 11-07-2024
- Dividend Yield
- CYRX N/A
- TRML N/A
- EPS Growth
- CYRX N/A
- TRML N/A
- EPS
- CYRX N/A
- TRML N/A
- Revenue
- CYRX $226,113,000.00
- TRML N/A
- Revenue This Year
- CYRX $0.34
- TRML N/A
- Revenue Next Year
- CYRX $8.47
- TRML N/A
- P/E Ratio
- CYRX N/A
- TRML N/A
- Revenue Growth
- CYRX N/A
- TRML N/A
- 52 Week Low
- CYRX $5.32
- TRML $12.12
- 52 Week High
- CYRX $20.11
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- CYRX 38.68
- TRML 37.25
- Support Level
- CYRX $6.31
- TRML $25.58
- Resistance Level
- CYRX $8.79
- TRML $27.51
- Average True Range (ATR)
- CYRX 0.59
- TRML 1.81
- MACD
- CYRX -0.11
- TRML -0.61
- Stochastic Oscillator
- CYRX 10.08
- TRML 10.76
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.